Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NYrNWG92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwNkGyN|ch|ryP M3HNXnNCVkeHUh?=
H4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[wSm5ZUUN3ME2wMlY3OjhizszN MUHTRW5ITVJ?
PA-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwOEewPVYh|ryP M1vrRXNCVkeHUh?=
NKM-1 MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknxTWM2OD1zLkC0PVMyKM7:TR?= M1m4cHNCVkeHUh?=
NEC8 NVTmell6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFwMkG1O|Ih|ryP M3qxdHNCVkeHUh?=
EoL-1-cell M{i4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\0TWM2OD1zLkK2O|AyKM7:TR?= M2W3OnNCVkeHUh?=
K5 NHHCVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTFwNEKwO|Ih|ryP MXzTRW5ITVJ?
QIMR-WIL NH3YfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPPSJRKSzVyPUGuOlA5PTRizszN NGC3XYdUSU6JRWK=
MOLT-16 MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfKNWNNUUN3ME2xMlc5PjB2IN88US=> NUTxfHRHW0GQR1XS
CHP-212 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn65TWM2OD1zLkixN|Y6KM7:TR?= NHL0NmpUSU6JRWK=
CTB-1 M3TIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjIbIhKSzVyPUKuNFIzPDZizszN MYTTRW5ITVJ?
MOLT-4 MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHI[HRKSzVyPUKuN|I5PTNizszN NUHSNJgzW0GQR1XS
A101D NFrYR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLFTWM2OD1{LkO1NFEh|ryP M1zSNnNCVkeHUh?=
DOHH-2 NFLtNXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJwNEKyO|kh|ryP NVz1[5ptW0GQR1XS
ES4 NYWxW2VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrqTWM2OD1{LkSzNVU2KM7:TR?= M1W4NHNCVkeHUh?=
SW780 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJwNUC4PFMh|ryP MUnTRW5ITVJ?
VA-ES-BJ MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHyTWM2OD1{LkW0NVEh|ryP NF7T[JBUSU6JRWK=
RPMI-8866 M{K0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke2TWM2OD1{LkW2NlE1KM7:TR?= NWLDWHM1W0GQR1XS
ML-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTNfGNCUUN3ME2yMlU3PTd4IN88US=> MlvUV2FPT0WU
MSTO-211H NYP5cphxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DKbGlEPTB;Mj61O|Q2OSEQvF2= NYDrcmFGW0GQR1XS
JVM-3 NEO3dXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rTcWlEPTB;Mj61PVMzPCEQvF2= NWfibmhVW0GQR1XS
A3-KAW M{DQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\SZ2lEPTB;Mj62NVgyQCEQvF2= MkDHV2FPT0WU
DK-MG NIPSR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrBdXR5UUN3ME2yMlYzPDdzIN88US=> NYPCfXVFW0GQR1XS
LNCaP-Clone-FGC M4HuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHJVIhPUUN3ME2yMlY1OzF6IN88US=> NFnLdoVUSU6JRWK=
HT-144 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJwNkS1O|ch|ryP MUnTRW5ITVJ?
NB69 NIPae|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fqdWlEPTB;Mj62OVM{PCEQvF2= Mn3ZV2FPT0WU
A172 NW\yWFdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwNke1PFgh|ryP NIjLclhUSU6JRWK=
RS4-11 M3Hy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJwN{K0NFch|ryP M4nSfXNCVkeHUh?=
DU-4475 MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTlTWM2OD1{Lke5OVAzKM7:TR?= M1HSbHNCVkeHUh?=
SJSA-1 M{DpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJwOEK1OVYh|ryP MVHTRW5ITVJ?
BV-173 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu2TWM2OD1{Lki0OFM6KM7:TR?= NFGwdJRUSU6JRWK=
U-2-OS NVrYc3NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPPRpZQUUN3ME2yMlkyODdizszN M1L0[XNCVkeHUh?=
CHP-134 Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrY[IlsUUN3ME2yMlk{QDh{IN88US=> MonHV2FPT0WU
D-502MG NETRRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLRdGpyUUN3ME2yMlk4OTV2IN88US=> MWPTRW5ITVJ?
KS-1 NHnTcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne5TWM2OD1|LkCxOlI{KM7:TR?= NGXZdmRUSU6JRWK=
A204 M2\UR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HXd2lEPTB;Mz6wOVU5QCEQvF2= M1ixdnNCVkeHUh?=
KGN NU\sVnJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPhTWM2OD1|LkC4OFk3KM7:TR?= M1XVOXNCVkeHUh?=
NCI-H292 M4Dvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfvTWM2OD1|LkGyNFI5KM7:TR?= Moq4V2FPT0WU
CAKI-1 M4i2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:4e2VKSzVyPUOuNVI3QTRizszN M175[HNCVkeHUh?=
C2BBe1 MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uyTmlEPTB;Mz6xO|AzPiEQvF2= NXT0WmR3W0GQR1XS
NB10 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTNwMkC5OlYh|ryP M{L6bXNCVkeHUh?=
MHH-NB-11 NH;FN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nLdWlEPTB;Mz6yOlgzPyEQvF2= MUnTRW5ITVJ?
NCI-SNU-1 NES1W5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTNwMke4OFMh|ryP Mnu2V2FPT0WU
HCT-116 M1Picmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLoRpdJUUN3ME2zMlMxOzN3IN88US=> NXrXVY5YW0GQR1XS
G-401 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXSWnZYUUN3ME2zMlM3OzJ{IN88US=> Mk\vV2FPT0WU
MN-60 NHLFeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PIemlEPTB;Mz60OFA6OiEQvF2= NFLKV5hUSU6JRWK=
SW982 NX\OZnNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f3b2lEPTB;Mz61NFg1QCEQvF2= MmfOV2FPT0WU
RKO NEntVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTNwNUO5N|Yh|ryP NYT5elVkW0GQR1XS
D-283MED MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y5O2lEPTB;Mz61O|k5PiEQvF2= Ml3qV2FPT0WU
LB996-RCC MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjPTWFoUUN3ME2zMlYzPTV6IN88US=> MY\TRW5ITVJ?
A549 NFLKS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PxU2lEPTB;Mz62N|U2OiEQvF2= MkHqV2FPT0WU
LB2241-RCC MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m4fGlEPTB;Mz62OVcxQCEQvF2= M3HETnNCVkeHUh?=
SK-HEP-1 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHTXoRWUUN3ME2zMlc1Ojl5IN88US=> NVnke5JTW0GQR1XS
G-402 NI\OZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f4cmlEPTB;Mz64NFg{OiEQvF2= NF\LRohUSU6JRWK=
GOTO Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\BNlVvUUN3ME2zMlg1OzN|IN88US=> NVjjc451W0GQR1XS
LOXIMVI M3LtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ixbGlEPTB;Mz64OVY4PSEQvF2= MV3TRW5ITVJ?
NH-12 MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3SPJZlUUN3ME20MlAyQTV7IN88US=> MUfTRW5ITVJ?
CTV-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTRwMEe5O|Mh|ryP NXf3ZoJrW0GQR1XS
CP50-MEL-B NVuxN5M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnCbGREUUN3ME20MlI1Ozl{IN88US=> MX\TRW5ITVJ?
RH-18 M1TrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTGTWM2OD12LkK3O|A3KM7:TR?= NFn1O41USU6JRWK=
NB17 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PzcWlEPTB;ND6zNVc3QCEQvF2= NV3VUGlJW0GQR1XS
A375 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTRwM{O1NlQh|ryP NVuxbI13W0GQR1XS
IST-MES1 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\lTWM2OD12LkSxOFEyKM7:TR?= M4O0dHNCVkeHUh?=
MZ2-MEL Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrqPGlKSzVyPUSuOVAyPTVizszN NVPwNpdbW0GQR1XS
CAL-54 MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTRwNUOwNVkh|ryP NHfFS25USU6JRWK=
NCI-H28 Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTRwNkK3NVch|ryP MX\TRW5ITVJ?
D-247MG MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP3WmdrUUN3ME20Mlc2ODd{IN88US=> MYTTRW5ITVJ?
NCI-H460 M2T0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojMTWM2OD12LkmxNVI4KM7:TR?= NULs[5JDW0GQR1XS
MCF7 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rJU2lEPTB;NT60OFI1PCEQvF2= NI\KWXRUSU6JRWK=
697 Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TQc2lEPTB;NT60OFU2KM7:TR?= M4\DSHNCVkeHUh?=
ONS-76 NUXORVk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofmTWM2OD13LkW3NFA6KM7:TR?= MVXTRW5ITVJ?
C32 M1;EVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTVwNkCwNlkh|ryP MlLrV2FPT0WU
OS-RC-2 NVy3WmJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTVwN{O4PFch|ryP Mof5V2FPT0WU
MEL-HO NUjqTmxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS5dGF{UUN3ME21Mlg2PjZ5IN88US=> MXnTRW5ITVJ?
LoVo NGLvSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H6UGlEPTB;Nj6wNVYzPCEQvF2= NG\L[HdUSU6JRWK=
AGS NID4T4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfUNYNTUUN3ME22MlE1QDJ6IN88US=> MmPsV2FPT0WU
GI-ME-N NVTCZZg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDHTWM2OD14LkKyOFIyKM7:TR?= NIHkV4NUSU6JRWK=
H-EMC-SS MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLKfG9KSzVyPU[uN|g3KM7:TR?= MkDvV2FPT0WU
RVH-421 Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjZUVBUUUN3ME22MlQzPDJ6IN88US=> MoraV2FPT0WU
SW954 NX3EellOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj1fpZKSzVyPU[uOVU2PzJizszN NFrqTVVUSU6JRWK=
NB5 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml20TWM2OD14LkW2NVg{KM7:TR?= NF7SWIxUSU6JRWK=
NCI-H2122 M2Xnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTrTWM2OD14LkW4O|k{KM7:TR?= NV3jZWFxW0GQR1XS
AM-38 M2K1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe1VGpLUUN3ME22Mlc2PjN7IN88US=> NFfTWlBUSU6JRWK=
KNS-81-FD MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHqTWM2OD14Lke2OFk1KM7:TR?= NX3QdoxQW0GQR1XS
LS-513 M3rMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTZwN{mwNlYh|ryP MkDQV2FPT0WU
A427 NYXZ[29wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\2TWM2OD14Lki3PFI6KM7:TR?= MUHTRW5ITVJ?
WM-115 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHaXlVKSzVyPU[uPVMzOyEQvF2= NFn2W5hUSU6JRWK=
COLO-829 M1r6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j6Z2lEPTB;Nz6yOFE5QCEQvF2= MkKxV2FPT0WU
NCI-H1650 M3jIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\XTWM2OD15LkO5NlI5KM7:TR?= MkHOV2FPT0WU
NCI-H358 M1XiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzoTWM2OD15LkS0PFc6KM7:TR?= NInwR3pUSU6JRWK=
HT-1080 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj0V2JSUUN3ME23MlQ5OjV2IN88US=> NFXW[VJUSU6JRWK=
HCC2218 MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ryR2lEPTB;Nz62Nlk4KM7:TR?= MVrTRW5ITVJ?
NCI-H661 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjFTWM2OD15Lki3NFY6KM7:TR?= NHjVPG9USU6JRWK=
KM-H2 MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\WTWM2OD15Lki4Olk1KM7:TR?= NUm0e|BSW0GQR1XS
RPMI-2650 M2rV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTdwOUS0NVQh|ryP MYLTRW5ITVJ?
NCI-H226 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnT[mMxUUN3ME24MlIyOTJ{IN88US=> NFrERpZUSU6JRWK=
MKN45 M2LSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHYdZoyUUN3ME24MlI3PjB{IN88US=> MYnTRW5ITVJ?
D-392MG NUDpPFVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nXPWlEPTB;OD61NlczOiEQvF2= MYDTRW5ITVJ?
RCC10RGB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRThwOE[2PVUh|ryP M{TZU3NCVkeHUh?=
CAL-51 NFHiZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\rTlBKSzVyPUmuNVAzPTFizszN NXfXeVZ[W0GQR1XS
COLO-678 MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPEdoVOUUN3ME25MlMzQDFzIN88US=> NVXTN41CW0GQR1XS
SK-MEL-24 NH7PWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTpRVlbUUN3ME25MlU2QDV4IN88US=> Moe3V2FPT0WU
SK-MEL-30 M1riUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGewVWVKSzVyPUmuPVQ1PzZizszN MV7TRW5ITVJ?
MMAC-SF NHja[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;1fohKSzVyPUGwMlM6PjFizszN MUPTRW5ITVJ?
NTERA-S-cl-D1 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHzc2NKSzVyPUGwMlY2ODhizszN MV3TRW5ITVJ?
NB12 NEnoOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m3bmlEPTB;MUGuOVA{KM7:TR?= MUDTRW5ITVJ?
UACC-257 NUixWVJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF64[JRKSzVyPUGxMlg3QTVizszN MlG4V2FPT0WU
LAN-6 M4SwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rPfmlEPTB;MUGuPVkzQCEQvF2= Mnz4V2FPT0WU
SW1573 NF\5fYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjjTWM2OD1zMj6zNFg3KM7:TR?= NX7TWYR[W0GQR1XS
NMC-G1 MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF{LkSxO|Uh|ryP M{\ON3NCVkeHUh?=
SHP-77 M{T5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLXOWlKSzVyPUGyMlU2PzRizszN NF;l[o1USU6JRWK=
IGROV-1 NIXNR|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjPTWM2OD1zMj62OVc{KM7:TR?= MnqxV2FPT0WU
22RV1 M2HRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv5TWM2OD1zMj64NFU6KM7:TR?= NYjwTZkyW0GQR1XS
SK-MEL-3 NILacnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\5cJlKSzVyPUGzMlM6PzNizszN NVy0ZmZ7W0GQR1XS
NCI-H1563 NYfvXpFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHneZdKSzVyPUGzMlQzODJizszN NV74WGE4W0GQR1XS
IGR-1 NEXVNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC4XmR7UUN3ME2xOE4xOzR5IN88US=> M{X3ZnNCVkeHUh?=
EW-3 NXfCTYlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MniyTWM2OD1zND6xOlM6KM7:TR?= NVzEeZRvW0GQR1XS
JEG-3 NUXtcHNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nje2lEPTB;MUSuOFk2OyEQvF2= MkK5V2FPT0WU
ES3 NFfxd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLKTWM2OD1zND62OVYzKM7:TR?= NHWz[nNUSU6JRWK=
MDA-MB-175-VII NF2xTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF2LkexNVEh|ryP NGq5RmJUSU6JRWK=
P30-OHK MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILSNotKSzVyPUG1MlA1QTZizszN MluzV2FPT0WU
GP5d M1zVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrXTWM2OD1zNT6xOFY3KM7:TR?= MWfTRW5ITVJ?
HMV-II MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF3LkOzN|Mh|ryP MnTvV2FPT0WU
COLO-679 NEDrW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnjZ21lUUN3ME2xOU42ODFizszN MWnTRW5ITVJ?
JAR M1n2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPGdI1tUUN3ME2xOU44OjB3IN88US=> NF6wU|RUSU6JRWK=
NCI-H1666 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF3LkmzPVkh|ryP NELtVGZUSU6JRWK=
SW48 NX3YfWxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrJTWM2OD1zNT65OVE3KM7:TR?= NWXOXYpyW0GQR1XS
NCI-H720 NXPvNHhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF3Lkm5PFkh|ryP MoHRV2FPT0WU
HT-1197 NVLEPJJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17KUGlEPTB;MU[uNFM2OiEQvF2= NE\0[FhUSU6JRWK=
HL-60 Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTwR4RKSzVyPUG2MlA{QDRizszN NILOd2ZUSU6JRWK=
BEN MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF4LkW2N|gh|ryP MmPGV2FPT0WU
HAL-01 M4f5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\5cFBlUUN3ME2xOk45QTB7IN88US=> NX[0SHQzW0GQR1XS
SW900 M3KzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XyUGlEPTB;MU[uPVE{OiEQvF2= NGPZe3BUSU6JRWK=
SBC-1 M4rnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PTZmlEPTB;MUeuOVQzQSEQvF2= NWrzXnNyW0GQR1XS
SH-4 NYfpfGFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTvRphJUUN3ME2xO{42QDRzIN88US=> NWTCSVJlW0GQR1XS
UACC-62 M1n1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr1TWM2OD1zNz63OlM4KM7:TR?= Mme0V2FPT0WU
BHT-101 NVXvPIRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\hdZV6UUN3ME2xPU45PzB3IN88US=> MlSzV2FPT0WU
DB MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL0NoZ1UUN3ME2yNU42PjR7IN88US=> MmrqV2FPT0WU
SK-MEL-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrP[HBKSzVyPUKxMlU5PzJizszN M1XwZXNCVkeHUh?=
NCI-H747 NWjTeZFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrpTWM2OD1{Mj63N|c6KM7:TR?= NWLVUmdjW0GQR1XS
SK-LU-1 NG\5R41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ|LkO1NlQh|ryP MUDTRW5ITVJ?
KG-1 MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzJ[|Z3UUN3ME2yN{41QTR4IN88US=> NE\0bZBUSU6JRWK=
LXF-289 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzWTHFKSzVyPUKzMlcyPCEQvF2= Ml;0V2FPT0WU
HCC1954 NI\yfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILUOXJKSzVyPUK0Mlg5PDRizszN NYDlNoFUW0GQR1XS
Ramos-2G6-4C10 M4q4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLNNGFKSzVyPUK2MlQ6QDFizszN MX;TRW5ITVJ?
DBTRG-05MG NGe0bmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorETWM2OD1{Nj62OFg5KM7:TR?= NXznNpBFW0GQR1XS
NCI-H2052 NX;SUpVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrZRZZKSzVyPUK3MlU3QDRizszN MYHTRW5ITVJ?
RMG-I MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLwU2poUUN3ME2yPU41OTN7IN88US=> MmTaV2FPT0WU
H9 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LVVGlEPTB;M{GuN|AxQCEQvF2= MYPTRW5ITVJ?
GR-ST Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi1TWM2OD1|Mj60OFU{KM7:TR?= MojQV2FPT0WU
Mo-T MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC1W3ZKSzVyPUOyMlUxPDZizszN NEWxcWhUSU6JRWK=
SW1088 NYDlUGF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHkTWM2OD1|Mj65PFAyKM7:TR?= MUHTRW5ITVJ?
LB2518-MEL M17IOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjuNXFKSzVyPUOzMlA4QTdizszN NVnTW4s2W0GQR1XS
NCI-H82 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj3SHdbUUN3ME2zN{4yPjZzIN88US=> MX3TRW5ITVJ?
LAMA-84 NY\WZnI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTN2Lk[wO|Mh|ryP M3fReHNCVkeHUh?=
KYSE-450 MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTN2Lk[3O|Yh|ryP NXfONWpXW0GQR1XS
LU-99A MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;WT2lEPTB;M{WuNFAxPyEQvF2= M2jq[HNCVkeHUh?=
BE-13 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\qOmRzUUN3ME2zOU43PTR3IN88US=> Mmq0V2FPT0WU
GAK NWD6d|NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vaNmlEPTB;M{WuOlk2KM7:TR?= M{LpOHNCVkeHUh?=
NCI-H1573 NXG0ZoNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTN3Lki4NVgh|ryP NVvGT4szW0GQR1XS
AsPC-1 NGLNVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjHNnFKSzVyPUO2MlE2OjdizszN NHzYNmVUSU6JRWK=
HDLM-2 M3j2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPKbm1KSzVyPUO2MlMyPiEQvF2= NWLHfoVtW0GQR1XS
NCI-H441 NYHCOVc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPMPVAyUUN3ME2zO{4xPjlzIN88US=> M1zoTnNCVkeHUh?=
CAL-27 M3z5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTN5LkeyN|Eh|ryP MlP2V2FPT0WU
OVCAR-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK1fWFKSzVyPUO5MlMyQDFizszN NFiwW5hUSU6JRWK=
RPMI-8226 MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLLTWM2OD1|OT61PVgh|ryP Mmr5V2FPT0WU
EFO-21 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LDXmlEPTB;NECuOVgyPCEQvF2= M1XN[XNCVkeHUh?=
SNU-C2B M3jP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzOeY97UUN3ME20NU42ODh2IN88US=> NXLOS4ZZW0GQR1XS
VM-CUB-1 NHXZUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHzTYVKSzVyPUSzMlgxOzdizszN NFPpO3dUSU6JRWK=
NCI-H2087 NES0NnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTVTWM2OD12NT6wNlM{KM7:TR?= NX30NHdTW0GQR1XS
EW-16 M2XlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLoeIFKSzVyPUS2MlMyOzdizszN M4HWdnNCVkeHUh?=
SK-N-AS MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe4PHJsUUN3ME20Ok44OTZ5IN88US=> MV;TRW5ITVJ?
COR-L105 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\PNJZ3UUN3ME20Ok45QDV5IN88US=> MkHzV2FPT0WU
DEL MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXIUYtKSzVyPUS4MlA1OjlizszN MV7TRW5ITVJ?
JVM-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjjfnhKSzVyPUS4MlA2PThizszN MXvTRW5ITVJ?
KARPAS-45 NH\VeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvFUnFNUUN3ME20PU41PTN6IN88US=> NIHqU3VUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / MDM2 / p21 / Bax / Bak / Noxa / cleaved caspase / pro-caspase; 

PubMed: 16014563     


Expression of apoptosis- and cell-cycle–associated proteins in OCI-AML-3 cells, which were treated with 5 μM Nutlin-3a for the indicated times. Nutlin-3a induced increased protein expression of p53, MDM2, and p21 in OCI-AML-3 cells in a time-dependent fashion. Nutlin-3a induced Noxa, a BH3-only member of the Bcl-2 family, followed by caspase activation. β-actin was used to confirm equal loading of proteins. Arrowheads indicate cleared caspases.

BMI-1; 

PubMed: 26887044     


Western blot analysis of BMI-1 and actin was performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after 24 hours treatment with increasing concentrations of Nutlin-3a (1 μM, 2 μM, 5 μM) and with DMSO control. 

p53-Ser15 / p53-Ser37 / p53-Lys382 / MDM2 / CDC2 / PLK1 / HSC70; 

PubMed: 23666059     


Expression of the indicated proteins in whole-cell lysates of cells treated for 96 h with 50 μM resveratrol (R), 5 μM nutlin-3a (N), or co-treated with both substances (RN).

16014563 26887044 23666059
Immunofluorescence
p-p21 / β-actin; 

PubMed: 31083332     


Cells were treated with fluoride (5 mM) with/without Nutlin-3a for 24 h. p-p21 (green), nucleus (DAPI; blue) and β-actin (red) expression were detected by immunocytochemistry. Nutlin-3a addition augmented p-p21 expression compared to NaF treatment alone.

P53; 

PubMed: 21394100     


At 12 h following treatment with nutlin-3a, DoHH2 and MCA cells had increased levels of p53 visualized by immunofluorescence. p53 localization was predominantly nuclear. The 4',6-diamidino-2-phenylindole was used as counterstain of the nuclei.

Ac-p300; 

PubMed: 30240745     


HepG2 cells were treated with 5 μM Nutlin-3a for 24 hr, and the levels of Ac-p300 and p53 were assessed by co-immunofluorescence. Fluorescence intensity of Ac-p300 in control cells versus Nutlin-3a-treated cells have been quantified (represented as mean ± SD, unpaired two-tailed Student's t test, n = 50 of three independent experiments). Scale bar, 10 μm.

31083332 21394100 30240745
Growth inhibition assay
Cell viability; 

PubMed: 26248031     


All 15 cell lines were plated in 96-well plates. After 24h, media was exchanged and cells were treated with incremental concentrations of Nutlin-3a (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, and 70 μM). After 72h of Nutlin-3a treatment, cell viability was measured by WST assay and compared to untreated control.

26248031
In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
- Collapse

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
- Collapse
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID